Primidone is one of the two first-line medications for essential tremor, and controlled trials consistently show it reduces hand tremor severity by roughly half. That sounds modest, but for a condition with limited pharmacological options, a 50 percent reduction can mean the difference between struggling to hold a cup of coffee and managing daily tasks with reasonable confidence. Primidone’s effectiveness is comparable to propranolol, the other front-line drug, though the two medications work through entirely different mechanisms and come with different trade-offs that matter when choosing between them.
What the Trials Actually Show
The clinical evidence for primidone in essential tremor goes back several decades and is remarkably consistent. In double-blind, placebo-controlled studies, primidone significantly reduced hand tremor magnitude compared to placebo, with efficacy comparable to propranolol.1PubMed Central. Primidone in essential tremor of the hands and head: a double blind controlled clinical study Quantitative tremor analysis in head-to-head comparisons confirms this: both propranolol and primidone produced statistically significant tremor improvement over placebo, with no significant difference between the two drugs.2PubMed Central. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis
When clinicians and guideline writers say primidone reduces tremor “by about half,” they mean the overall severity score drops by roughly 50 percent on average.3PubMed. Treatment of essential tremor: current status Some people respond much better than that. In one controlled study, two patients saw their tremor reduced to non-symptomatic levels, an outcome the investigators noted was rarely achieved with propranolol.1PubMed Central. Primidone in essential tremor of the hands and head: a double blind controlled clinical study Others get little or no benefit. A retrospective analysis of over a thousand prescriptions for essential tremor found that about one in six prescriptions was deemed ineffective.4PubMed Central. Treatment Patterns in Essential Tremor: A Retrospective Analysis That variability is the norm for essential tremor treatments, and it means patience and dose adjustment are part of the process.
What Makes Primidone Work, and Why It Is Not Just Phenobarbital
Primidone was originally developed as an anti-seizure drug in the 1950s, and its use for tremor was discovered somewhat serendipitously. In the body, primidone is partly converted into phenobarbital, which led to an early assumption that the tremor benefit was really coming from the phenobarbital metabolite. That turns out to be wrong, and the distinction matters clinically.
A key pharmacokinetic study demonstrated this clearly: a single 250 mg dose of primidone reduced tremor by about 60 percent within one to seven hours, at a time when serum primidone levels were stable but phenobarbital was not yet detectable in the blood. When researchers then substituted phenobarbital directly for primidone, tremor control was lost.5PubMed. Efficacy of primidone in essential tremor This tells us that primidone itself, not its breakdown products, is doing most of the heavy lifting against tremor. More recent work has identified the likely mechanisms: primidone blocks voltage-gated sodium channels and modulates inhibitory brain circuits involving GABA.6Parkinsonism & Related Disorders. Mechanisms of tremor-modulating effects of primidone and propranolol in essential tremor
This is more than an academic detail. It explains why primidone can work for people who have not responded to phenobarbital alone, and why switching from primidone to phenobarbital (sometimes attempted by doctors unfamiliar with the distinction) tends to make tremor worse. It also explains the rapid onset: within hours of the first dose, some patients notice improvement, well before any phenobarbital has accumulated.
The First-Dose Problem
If primidone works as well as propranolol, why doesn’t everyone just start with it? The answer is a notorious first-dose reaction that scares off many patients before the drug has a chance to help. In one study, 10 out of 13 patients experienced a peak of acute side effects after only two doses, including nausea, vomiting, dizziness, and sedation so severe that some patients refused to continue.7PubMed. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels Paradoxically, this initial burst of side effects occurs at the same time the drug is showing its strongest early tremor-suppressing effect.
The severity of this reaction is a genuine obstacle. In the large retrospective analysis of essential tremor prescriptions, about 13 percent of all prescriptions were discontinued specifically because of side effects.4PubMed Central. Treatment Patterns in Essential Tremor: A Retrospective Analysis Primidone’s first-dose reaction is a major contributor to those discontinuations. Typical symptoms include overwhelming drowsiness, unsteadiness, confusion, and nausea that can last a day or two. These side effects usually fade substantially after the first few doses, but getting through that window is the challenge.
There is something interesting about who gets hit hardest. People with essential tremor appear to be more intolerant of primidone than people taking the same drug for epilepsy. Several potential explanations have been proposed for this, including the fact that essential tremor patients tend to be older and may have underlying differences in brain GABA signaling that make them more sensitive to primidone’s central nervous system effects.8Tremor and Other Hyperkinetic Movements. Primidone Intolerance in Essential tremor: Is it More than Just Age?
A Workaround for the First-Dose Reaction
Because the first-dose reaction is the single biggest barrier to primidone use, researchers have looked for ways around it. The standard clinical approach is to start at a very low dose, sometimes as little as 25 to 62.5 mg at bedtime, and increase slowly over weeks. But a more targeted strategy has shown striking results: pre-treating patients with phenobarbital before introducing primidone.
In a study comparing patients who received phenobarbital beforehand with those who did not, the difference was dramatic. Among patients who jumped straight into primidone, 82 percent reported neurotoxic symptoms like somnolence, unsteadiness, confusion, and nausea. Among those pre-treated with phenobarbital, only 17 percent experienced those symptoms. The pre-treated group also had fewer side effects per person and lower severity scores. Two patients who had previously failed primidone because of intolerable side effects were able to tolerate it without problems after phenobarbital pre-treatment.9PubMed. Does pre-treatment with phenobarbital prevent the acute intolerance to primidone in patients with essential tremor?
The logic is that phenobarbital pre-exposure builds a degree of cross-tolerance, priming the brain’s receptors so the first dose of primidone does not land with such a neurological jolt. This aligns with the observation that epilepsy patients, who often already take other sedating anti-seizure drugs, rarely have the same dramatic first-dose reaction. If you are considering primidone and are worried about the initial side effects, this is worth discussing with your neurologist, though the strategy is not yet universally adopted in clinical practice.
How Primidone Compares to Propranolol in Practice
Propranolol and primidone are the two medications with the strongest evidence for essential tremor, and guidelines treat them as interchangeable first choices. Controlled trials repeatedly show they reduce tremor by similar amounts.2PubMed Central. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis But “similar average efficacy” hides some practical differences that can make one a better fit than the other for a given person.
Propranolol is a beta-blocker, meaning it works on the heart and peripheral nervous system. It cannot be used by people with asthma, certain heart rhythm disorders, poorly controlled diabetes, or some vascular conditions. For those patients, primidone becomes the go-to alternative.7PubMed. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels Conversely, primidone’s sedating properties and the first-dose reaction make it a harder sell for people who need to stay sharp during the day or who have had bad experiences with anti-seizure drugs.
Primidone may produce faster initial tremor suppression. One study found it was significantly more effective than propranolol after just two doses, though the two drugs reached similar effectiveness after one to two weeks of continued use.7PubMed. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels In practice, the choice often comes down to a patient’s other medical conditions, their sensitivity to sedation, and whether they can tolerate the rocky initiation period primidone demands.
Combining the two drugs is sometimes tried when neither alone provides adequate control, since they work through entirely different pathways. Propranolol blocks the adrenaline-driven component of tremor peripherally, while primidone acts centrally on sodium channels and GABA circuits.6Parkinsonism & Related Disorders. Mechanisms of tremor-modulating effects of primidone and propranolol in essential tremor Evidence for combination therapy is less robust than for either drug alone, but it is a common clinical strategy when monotherapy falls short.
How Widely Primidone Is Actually Used
Despite its reputation for difficult side effects, primidone is the most frequently prescribed medication for essential tremor. A retrospective analysis of prescribing patterns found that primidone accounted for nearly half of all essential tremor prescriptions, outpacing propranolol, which made up about a third. Second-line drugs like topiramate and gabapentin trailed far behind at roughly 10 percent and 3 percent respectively.4PubMed Central. Treatment Patterns in Essential Tremor: A Retrospective Analysis This suggests that, despite the first-dose challenges, many clinicians consider primidone their preferred starting option, likely because a substantial fraction of patients tolerate it well once past the initial hurdle.
It is worth noting that prescribing patterns vary by country, institution, and individual neurologist preference. In some settings, propranolol is the default first choice because patients can tolerate it more easily from the outset. The data above comes from a specialty movement-disorder clinic population, which may skew toward primidone because those clinicians are experienced at managing the initiation phase.
Does Primidone Work for Other Types of Tremor?
Essential tremor is where primidone shines, but people often wonder whether it helps with other tremor conditions, particularly Parkinson’s disease. The answer is generally no. In a controlled study looking at parkinsonian tremor, long-acting propranolol significantly reduced both resting and postural tremor scores, but primidone did not change tremor amplitudes.10JAMA Neurology. Adjuvant Therapy of Parkinsonian Tremor This makes sense given that Parkinson’s tremor arises from a fundamentally different circuit problem involving dopamine-producing cells, not the oscillatory networks that primidone targets.
For rarer tremor types, the evidence is thinner. Orthostatic tremor, a condition that causes leg shakiness on standing, is generally treated with clonazepam or gabapentin. Primidone has been considered potentially helpful, though it is not a first-line choice for that condition.11Journal of the Neurological Sciences. Medications used to treat tremors Dystonic tremor and cerebellar tremor are even less studied with primidone, and most movement-disorder specialists would not reach for it as an initial treatment in those cases.
The practical takeaway is that getting the tremor diagnosis right matters. If your tremor has been labeled “essential tremor” and primidone is not working, it is worth revisiting the diagnosis. Some conditions initially mistaken for essential tremor, such as dystonic tremor or enhanced physiological tremor, respond to different medications entirely.
When Primidone Is Not Enough
About half the improvement in tremor severity still leaves many patients with meaningful disability, especially as essential tremor tends to worsen over the years. The first line of treatment is pharmacotherapy with propranolol or primidone, but because these drugs typically reduce severity by only about half, functionally disabling tremor that persists despite medication may warrant considering interventional approaches.3PubMed. Treatment of essential tremor: current status
The surgical options have expanded considerably. Deep brain stimulation involves implanting electrodes in a specific brain region, the ventral intermediate nucleus of the thalamus, and is considered the gold standard for medication-refractory essential tremor. It can be used for tremor affecting both sides. MRI-guided focused ultrasound is a newer, incisionless technique that uses targeted sound waves to create a small lesion in the same thalamic target. It is approved for one-sided treatment, meaning it can address the more affected hand but not both simultaneously. Traditional thalamotomy, the surgical creation of a lesion, is another option for unilateral cases.
These interventions are not alternatives to trying medication first. Guidelines recommend exhausting pharmacotherapy, including adequate trials of primidone and propranolol at therapeutic doses, before moving to surgical evaluation. “Adequate trial” is a key phrase here: many patients are underdosed or give up during the initiation phase. A neurologist experienced with essential tremor may be able to optimize your medication regimen in ways a general practitioner might not attempt.
Ongoing Side Effects Beyond the First Dose
The first-dose reaction gets the most attention, but primidone has a side-effect profile that extends into long-term use. Sedation and drowsiness are the most common ongoing complaints, though they tend to lessen as the body adjusts. Some people experience persistent fatigue, mild cognitive dulling, or unsteadiness at higher doses. These are dose-dependent effects, meaning they can often be managed by finding the lowest effective dose rather than pushing to the maximum.
Because primidone is partially metabolized to phenobarbital, which accumulates in the body over weeks, blood levels of phenobarbital gradually rise even on a stable primidone dose. This can contribute to creeping sedation that was not present initially. Monitoring drug levels is occasionally useful, particularly if a patient seems disproportionately sedated or if the drug seems to be losing effectiveness.
One concern specific to older adults is fall risk. The combination of sedation and mild unsteadiness is a familiar recipe for falls, and since essential tremor is most common in people over 60, this creates a real clinical tension. The tremor itself impairs function and quality of life, but the treatment can introduce a different kind of impairment. Balancing these trade-offs is a conversation that looks different for a 45-year-old professional whose hand tremor affects their work versus an 80-year-old with balance problems.
Dosing in Practice
The typical approach is to start very low and go slow. Many neurologists begin at 25 mg or 62.5 mg taken at bedtime, then increase by small increments every week or two. Therapeutic doses generally range from 250 mg to 750 mg per day, divided into two or three doses. Some patients respond well at low doses, and there is no reason to push higher if the tremor is adequately controlled.
In the clinical trials that established primidone’s efficacy, doses up to 750 mg daily were used, but the dose-response curve is not perfectly linear. Some people get their maximum benefit at 250 mg and see only side effects from further increases. Others need the higher range. The general strategy is to titrate upward until tremor is adequately controlled, side effects become limiting, or the maximum tolerated dose is reached.
Timing matters too. Taking the largest portion of the daily dose at bedtime minimizes daytime sedation, since the peak drowsiness occurs while you are sleeping. Some people find that a single bedtime dose controls their tremor adequately through the next day, avoiding the need for divided dosing entirely.
Why Some Patients Respond and Others Do Not
Essential tremor is increasingly recognized as a heterogeneous condition, not a single disease. Different patients may have tremor driven by different underlying circuit abnormalities, which would explain why some respond beautifully to primidone and others get nothing from it. The same variability applies to propranolol. There are no reliable predictors, at present, of who will respond to which drug. The clinical approach remains empirical: try one, and if it does not work or is not tolerated, try the other.
Age at onset, tremor frequency, family history, and presence of head tremor versus hand tremor have all been investigated as potential predictors, but none has proven consistently useful in guiding drug selection. This is frustrating for patients who want a more targeted approach, but it reflects the current state of the science. Essential tremor research has lagged behind conditions like Parkinson’s disease in identifying the precise biological subtypes, partly because essential tremor, while disabling, is not life-threatening and has historically attracted less research funding.
For people who do not respond to either primidone or propranolol, the second-line options include topiramate, gabapentin, and benzodiazepines, though none has evidence as strong as the two first-line drugs. Botulinum toxin injections are sometimes used for head or voice tremor that does not respond to oral medication. And for severely affected individuals, the surgical interventions described earlier remain an option that can produce dramatic improvement in selected patients.